Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline.

Ascendis Pharma's TransCon platform shows promise, but challenges with rollout, competition, and execution risks lead to a Hold rating.

A campaign with a celebrity of Williams' stature could be a turning point in the marketing of GLP-1 drugs, which have ...

"This retrospective cohort study found that taking GLP-1RAs was associated with a reduced overall risk of cancer, including ...